Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria

Pitout, 2008, Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern, Lancet Infect Dis, 8, 159, 10.1016/S1473-3099(08)70041-0 Melzer, 2007, Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli, J Infect, 55, 254, 10.1016/j.jinf.2007.04.007 Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, J Clin Microbiol, 39, 2206, 10.1128/JCM.39.6.2206-2212.2001 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009. Robberts, 2009, Unreliable extended-spectrum β-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates, J Clin Microbiol, 47, 358, 10.1128/JCM.01687-08 Andes, 2005, Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations, Clin Microbiol Infect, 11, 10, 10.1111/j.1469-0691.2005.01265.x Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010. Ho, 2011, Effect of applying the new Clinical and Laboratory Standards Institute ceftazidime and ceftriaxone susceptibility breakpoints for Escherichia coli in Hong Kong, Int J Antimicrob Agents, 37, 270, 10.1016/j.ijantimicag.2010.11.016 Huang, 2012, Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002–2010, Int J Antimicrob Agents, 40, S4, 10.1016/S0924-8579(12)70003-1 Wang, 2011, Susceptibility of extended-spectrum β-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints, J Clin Microbiol, 49, 3127, 10.1128/JCM.00222-11 Livermore, 2012, Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?, J Antimicrob Chemother, 67, 1569, 10.1093/jac/dks088 Agodi, 2011, Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy, J Clin Microbiol, 49, 3986, 10.1128/JCM.01242-11 Perilli, 2002, Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey, J Clin Microbiol, 40, 611, 10.1128/JCM.40.2.611-614.2002 Cantón, 2008, Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe, Clin Microbiol Infect, 14, 144, 10.1111/j.1469-0691.2007.01850.x de Oliveira, 2010, High frequency of β-lactam susceptibility in CTX-M-type extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations, J Antimicrob Chemother, 65, 2481, 10.1093/jac/dkq343